Dermatitis News

This report provides elemental information and data relating to the clinical trials on Dermatitis.

Anacor Pharmaceuticals announced positive preliminary results from a Phase 2a trial of its two boron-based phosphodiesterase-4 inhibitors, AN2728 and AN2898, in mild-to-moderate atopic dermatitis, a chronic rash characterized by inflammation and itching.

Also sometimes called eczema, AD's most common symptoms are itching -- often intense, especially at night -- inflammation, dry skin, and rash.

Main complaint: A 25 years old male complains of eczema, which comes and goes particularly during stressful periods.

According to a filing with the Security and Exchange Commission, Stern was dismissed "in connection with an Audit Committee investigation concerning conduct by Mr.